Trust Co. of Toledo NA OH Sells 416 Shares of Pfizer Inc. $PFE

Trust Co. of Toledo NA OH trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 153,930 shares of the biopharmaceutical company’s stock after selling 416 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in Pfizer were worth $3,731,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Aberdeen Group plc grew its stake in shares of Pfizer by 6.9% in the second quarter. Aberdeen Group plc now owns 5,272,611 shares of the biopharmaceutical company’s stock worth $128,098,000 after purchasing an additional 338,461 shares during the last quarter. Lmcg Investments LLC grew its stake in shares of Pfizer by 3.8% in the second quarter. Lmcg Investments LLC now owns 62,597 shares of the biopharmaceutical company’s stock worth $1,517,000 after purchasing an additional 2,284 shares during the last quarter. First Fiduciary Investment Counsel Inc. grew its stake in shares of Pfizer by 2.1% in the second quarter. First Fiduciary Investment Counsel Inc. now owns 237,043 shares of the biopharmaceutical company’s stock worth $5,746,000 after purchasing an additional 4,928 shares during the last quarter. Strengthening Families & Communities LLC grew its position in shares of Pfizer by 871.3% in the 2nd quarter. Strengthening Families & Communities LLC now owns 2,370 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,126 shares during the last quarter. Finally, Blue Trust Inc. grew its position in shares of Pfizer by 3.1% in the 2nd quarter. Blue Trust Inc. now owns 118,351 shares of the biopharmaceutical company’s stock valued at $2,869,000 after buying an additional 3,548 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on PFE. Morgan Stanley reduced their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.35.

Pfizer Price Performance

Pfizer stock opened at $24.81 on Friday. The stock has a market capitalization of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.83 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.82. The stock’s 50 day moving average price is $24.86 and its two-hundred day moving average price is $24.14. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.